// App-Quantinova.ai

9064 : Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.

Researchers

Presenter

  • Daniel Shao-Weng Tan

Principal Investigators

  • Dong-Wan Kim

  • Michael Thomas

  • Serafino Pantano

  • Ying Wang

  • Sebastian Lukasz Szpakowski

  • Alejandro Javier Yovine

  • Ranee Mehra

  • Laura Q. Chow

  • Sunil Sharma

  • Benjamin J. Solomon

  • Enriqueta Felip

  • D. Ross Camidge

  • Johan F. Vansteenkiste

  • Hans Bitter

  • Lilli M. Petruzzelli

  • Margaret Han Dugan

  • Alice T. Shaw

Medical Centers

  • National Cancer Centre Singapore, Singapore, Singapore

  • University Clinic Heidelberg, Heidelberg, Germany

  • Novartis AG, Basel, Switzerland

  • Novartis, Cambridge, MA

  • Fox Chase Cancer Center, Philadelphia, PA

  • University of Washington, Seattle, WA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • University of Colorado Cancer Center, Aurora, CO

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Novartis, East Hanover, NJ

  • Massachusetts General Hospital, Boston, MA

Locations

  • Singapore

  • Germany

  • Spain

  • Switzerland

  • Australia

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

Drug/Treatment

  • Ceritinib

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved